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Cells talk to each other, but do members
of the scientific community communicate
with each other? Do molecular and cellu-
lar biologists speak with clinicians? In the
last few years, numerous research centers
have been located close to hospitals leading
toward a more fluid connection between
clinical and basic researchers, and there-
fore, translational medicine is becoming
increasingly prominent.
Progress in translational medicine cru-
cially depends on close collaborations
between three areas: technology devel-
opment, research, and hospitals. This
combination allows a research idea (or
hypothesis) to be developed into a real
concept (or product), thus producing sub-
stantial benefits to citizens. Such synergy
between these areas is beginning to be
found in health research institutes located
in close vicinity to hospitals. These insti-
tutes usually house several core units, also
known as platforms or facilities, which pro-
vide scientific support not only to their
own researchers but also to hospitals and
medtech companies.
Our cell culture platform participates in
the three areas previously mentioned. On
one hand, scientific, medical, or technolog-
ical companies are constantly developing
new products (such as cell culture dishes,
factors, and antibodies) and advanced
research tools. Prior to their commercial-
ization, or in order to determine their effi-
cacy, companies often need a network of
scientific partners to test the products. The
cell culture platform in our institute, for
example, fostered by its physical proxim-
ity to technological companies, works as a
service that tests those new products and
tools.
On the other hand, research areas of
the institutes require cell culture platform
infrastructure in order to proceed with its
research lines linked to cell cultures.
Hospitals are the third area related to
the cell culture platform. Currently, the ser-
vices offered by the cell culture platform are
highly demanded by clinicians working in
the hospital. For example, we assist in the
expansion of clinical samples. Clinicians
face difficulties to obtain large amounts
of biological material (for example, blood
samples of newborns, or amniotic liquid)
in order to obtain DNA or RNA to per-
form a diagnosis. In undiagnosed new-
borns, pediatricians may decide to perform
skin biopsies in order to establish cell cul-
tures and this way, get enough DNA or RNA
for the diagnosis. The cell culture platform
offers all the basic equipment needed to
process these biopsy samples, expand the
cells in vitro and get enough genetic mater-
ial for the genetic analysis. Moreover, these
samples are deposited in the Biobank in
order to be preserved for future diagnostic
tests or for research purposes.
Additionally, increasing developments
on cell transplantation-based therapies in
hospitals is leading to hand-in-hand co-
working between clinicians and scientists
through cell culture platforms and is evok-
ing an internal transformation. Currently,
the therapeutic potential of several cell
types is being tested in hospitals. Some
examples include the injection of chon-
drocytes for bone regeneration, and the
transplantation of human heart stem cells
to treat myocardial infarctions.
Lately, innovative therapies based on
the transplantation of extracellular vesi-
cles (EVs) are emerging. In 2007, Valadi
and colleagues (1) described a new mech-
anism of cells-to-cell communication con-
sisting in the transfer of genetic material
through EVs, which can be either intracel-
lularly generated or extracellularly formed
from the cell membrane. Actually, EVs have
been detected in most body fluids, includ-
ing blood and urine, and they have become
a target to identify diagnostic biomark-
ers. During the last years, an increasing
number of publications are demonstrat-
ing their importance, especially for exo-
somes (cell-derived vesicles of 30–100 nm
of diameter) as prognostic markers or as
therapeutic tools to treat cancer and vas-
cular diseases (2, 3). EVs are optimal thera-
peutic vectors due to their ability to present
MHC antigens, which prevents immune
rejection when used in allogeneic trans-
plantations (4). To date, three cell types –
regulatory T-cells, mesenchymal stem cells
(MSC), and dendritic cells – have been
used as sources of EVs for transplantation.
In order to standardize EV-based thera-
pies, several parameters need to be con-
trolled. These include, but are not lim-
ited to, EV extraction and processing pro-
tocols, EV identification protocols, purity
assessment, route of administration, and
doses.
From a clinical perspective, the per-
formance of a clinical trial requires a
quality control of the exosomes that
are going to be injected in patients.
This quality control should include at
least a flow cytometry-based characteriza-
tion, an ELISA-based quantification, and
a nanoparticle tracking, besides purity
assessment and exhaustive analysis to
ensure the absence of mycoplasma, adven-
titious agents, and endotoxins (5).
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FIGURE 1 | Cell culture platform is placed in between research, hospital, and technological areas.
EVs therapies derived from hospitals could transform part of the cell culture platform in a EVs sample
quality service and simultaneously EV resuspension point prior to human injection.
The establishment of EV-based ther-
apies will lead to standardized produc-
tion and manipulation protocols following
good manufacturing practices (GMPs), as
well as quality controls to ensure the safety
and efficacy of the treatments. Hence, how
will these therapies impact cell culture
platforms?
From my point of view, there could
be two options for our platform, as cell
extraction and culture, batch-production
of EVs and packaging will have to be per-
formed in GMP conditions: the first one
is to adapt these requirements to a white
room that will operate in line with GMP
guidelines. That can be extremely costly.
The second option will be to use the cell
culture platform just as a service to perform
EVs quality control whereas EVs obtain-
ing from cells and packing is performed in
a Contract Development and Manufactur-
ing Organization (CDMO) specialized in
the process development and GMP manu-
facture of cell therapy products from early
stages up to clinical and commercial. In this
case, the platform will only have to make
a small investment to incorporate specific
apparatus to determine EVs size and other
EV-specific parameters.
In addition, even if the EVs production
and packing is performed in an external
CDMO, resuspension of the cryopreserved
EVs can be performed in the platform
in our biosecurity flow hoods. This way,
the EVs delivery to the hospital, ready to
inject, will be achieved a minimum time,
as we are already operating with other
cell therapies. This new challenge will have
to be supported by specialized personnel
in cell culture and EV related machinery
as flow cytometry and EV related specific
tools.
Bearing all this in mind if the cell cul-
ture platform would have to go toward
EVs therapy, I would transform part of the
platform in a “EVs sample quality service”
(Figure 1). Otherwise, a big construction
work with its high costs and complications
would be difficult to face.
In conclusion, EVs therapies may have
a great impact in the close future as new
cell-based therapeutic approach; therefore,
I will keep a sharp eye on EVs thera-
pies future publications to envision the
transformation of our cell culture platform
toward a “EVs quality service.”
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